Influence of variants of Fcγ receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to antitumour necrosis factor α therapy in rheumatoid arthritis

被引:85
作者
Canete, J. D. [1 ]
Suarez, B. [2 ]
Hernandez, M. V.
Sanmarti, R.
Rego, I. [3 ]
Celis, R.
Moll, C.
Pinto, J. A. [3 ]
Blanco, F. J. [3 ]
Lozano, F. [2 ]
机构
[1] Univ Barcelona, Hosp Clin Barcelona, Serv Reumatol, IDIBAPS,Sch Med,Unitat Artritis, E-08036 Barcelona, Spain
[2] Univ Barcelona, Hosp Clin Barcelona, Dept Immunol, IDIBAPS,Sch Med, E-08036 Barcelona, Spain
[3] Hosp Juan Canalejo, Dept Rheumatol, La Coruna, Spain
关键词
BLOCKING AGENTS; HUMAN IGG2; BINDING; METHOTREXATE; POLYMORPHISM; GENOTYPE; TRIAL; RIIA;
D O I
10.1136/ard.2008.096982
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Objective: Fc gamma receptor (Fc gamma R) polymorphism influences the affinity of the receptor for Ig, which may, in turn, affect the efficacy of Ig-based therapies. The relationship between functional single nucleotide polymorphisms (SNP) of the FCGR2A and FCGR3A genes and the response to anti-tumour necrosis factor (TNF)alpha therapy (infliximab) in patients with rheumatoid arthritis (RA) was assessed. Methods: A total of 91 patients with RA (89% female; 76.7% rheumatoid factor (RF) positive) starting therapy with infliximab were evaluated at 0, 6 and 30 weeks using the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) response criteria and the 28-joint Disease Activity Score (DAS28) was evaluated using three parameters, including C-reactive protein (CRP) (DAS28 3v-CRP) changes during the follow-up. Genotyping of FCGR2A-R131H and FCGR3A-F158V polymorphisms was performed by allele-specific PCR and PCR sequence-based typing, respectively. The chi(2) and Fisher exact tests were used to show differences in the outcome variables, and analysis of variance (ANOVA) to analyse the evolution of DAS28 3v-CRP. A generalised linear models multivariable analysis was also performed. Results: At week 6 of follow-up, the proportion of patients achieving 50% improvement as per ACR criteria (ACR50) and EULAR good responses were significantly higher among homozygotes of the low affinity FCGR3A allele (FF: 24.1% and VV-VF: 2.2%; p = 0.003 and FF: 44.8% and VV-VF: 22.9%; p = 0.040, respectively). At week 30, homozygotes of the low affinity FCGR2A allele had a better ACR20 response (RR: 60% and HH-RH: 33.3%; p = 0.035). Changes in DAS28 3v-CRP during follow-up were consistent with those observed in ACR and EULAR responses. Conclusions: The response to anti-TNF alpha treatment with infliximab in patients with RA is influenced by the FCGR2A and FCGR3A genotypes. This effect is observed at different times in the follow-up (6 and 30 weeks, respectively) indicating the dynamic nature of the Fc gamma R versus Ig interaction.
引用
收藏
页码:1547 / 1552
页数:6
相关论文
共 16 条
[1]
Differential binding to human FcγRIIa and FcγRIIb receptors by human IgG wildtype and mutant antibodies [J].
Armour, KL ;
van de Winkel, JGJ ;
Williamson, LM ;
Clark, MR .
MOLECULAR IMMUNOLOGY, 2003, 40 (09) :585-593
[2]
Response criteria for rheumatoid arthritis in clinical practice:: how useful are they? [J].
Gülfe, A ;
Geborek, P ;
Saxne, T .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (08) :1186-1189
[3]
Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the FcγRIIIa-158 V/V and V/F polymorphism [J].
Hatjiharissi, Evdoxia ;
Xu, Lian ;
Santos, Daniel Ditzel ;
Hunter, Zachary R. ;
Ciccarelli, Bryan T. ;
Verselis, Sigitas ;
Modica, Michael ;
Cao, Yang ;
Manning, Robert J. ;
Leleu, Xavier ;
Dimmock, Elizabeth A. ;
Kortsaris, Alexandros ;
Mitsiades, Constantine ;
Anderson, Kenneth C. ;
Fox, Edward A. ;
Treon, Steven P. .
BLOOD, 2007, 110 (07) :2561-2564
[4]
Fcγ receptor type IIIA genotype and response to tumor necrosis factor α-blocking agents in patients with rheumatoid arthritis [J].
Kastbom, Alf ;
Bratt, Johan ;
Ernestam, Sofia ;
Lampa, Jon ;
Padyukov, Leonid ;
Soderkvist, Peter ;
Skogh, Thomas .
ARTHRITIS AND RHEUMATISM, 2007, 56 (02) :448-452
[5]
Fc gamma RIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gamma RIIIa, independently of the Fc gamma IIIa-48L/R/H phenotype [J].
Koene, HR ;
Kleijer, M ;
Algra, J ;
Roos, D ;
vondemBorne, AEGK ;
deHaas, M .
BLOOD, 1997, 90 (03) :1109-1114
[6]
Rheumatoid arthritis [J].
Lee, DM ;
Weinblatt, ME .
LANCET, 2001, 358 (9285) :903-911
[7]
A novel PCR-based method for direct Fcγ receptor IIIa (CD163) allotyping [J].
Leppers-van de Straat, FGJ ;
van der Pol, WL ;
Jansen, MD ;
Sugita, N ;
Yoshie, H ;
Kobayashi, T ;
van de Winkel, JGJ .
JOURNAL OF IMMUNOLOGICAL METHODS, 2000, 242 (1-2) :127-132
[8]
Infliximab and methotrexate in the treatment of rheumatoid arthritis [J].
Lipsky, PE ;
van der Heijde, DMFM ;
St Clair, EW ;
Furst, DE ;
Breedveld, FC ;
Kalden, JR ;
Smolen, JS ;
Weisman, M ;
Emery, P ;
Feldmann, M ;
Harriman, GR ;
Maini, RN .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) :1594-1602
[9]
ON THE INTERACTION OF IGG SUBCLASSES WITH THE LOW AFFINITY FC-GAMMA-RIIA (CD32) ON HUMAN MONOCYTES, NEUTROPHILS, AND PLATELETS - ANALYSIS OF A FUNCTIONAL POLYMORPHISM TO HUMAN IGG2 [J].
PARREN, PWHI ;
WARMERDAM, PAM ;
BOEIJE, LCM ;
ARTS, J ;
WESTERDAAL, NAC ;
VLUG, A ;
CAPEL, PJA ;
AARDEN, LA ;
VANDEWINKEL, JGJ .
JOURNAL OF CLINICAL INVESTIGATION, 1992, 90 (04) :1537-1546
[10]
Biologic therapies in rheumatology: lessons learned, future directions [J].
Strand, Vibeke ;
Kimberly, Robert ;
Isaacs, John D. .
NATURE REVIEWS DRUG DISCOVERY, 2007, 6 (01) :75-92